<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619406</url>
  </required_header>
  <id_info>
    <org_study_id>UI/EC/18/0706</org_study_id>
    <nct_id>NCT05619406</nct_id>
  </id_info>
  <brief_title>Systematic Investigation of Blacks With Stroke - GENOMICS</brief_title>
  <acronym>SIBSGENOMICS</acronym>
  <official_title>Systematic Investigation of Blacks With Stroke - GENOMICS (SIBS-GENOMICS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Hospital, Ibadan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ibadan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal Medical Centre, Abeokuta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ahmadu Bello University Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayero University Kano, Nigeria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kwame Nkrumah University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korle-Bu Teaching Hospital, Accra, Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Hospital, Ibadan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of SIBS-GENOMICS is to utilize the best available contextual data on stroke&#xD;
      in Africa to develop &amp; validate stroke risk estimation models, translate the best model into&#xD;
      a mobile phone app and conduct a randomized control trial of the app with a co-created&#xD;
      motivational education video, to determine their effectiveness for improvement of stroke risk&#xD;
      factor awareness and global risk reduction among Africans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Africa now bears a foremost burden of stroke worldwide with age standardized stroke incidence&#xD;
      rate of up to 316 per 100,000, a prevalence of 1.46 per 1,000 population,1 month fatality of&#xD;
      40% &amp; a 3-year mortality rate of 84%.&#xD;
&#xD;
      The burden of stroke on the continent falls heavily on the young productive age group &amp; is&#xD;
      associated with profound diminution in the quality of life via disability, depression, &amp;&#xD;
      vascular cognitive impairment.&#xD;
&#xD;
      World Health Organization estimates that stroke deaths in LMIC account for 86% of stroke&#xD;
      deaths worldwide &amp; disability-adjusted life years lost in LMIC is 7X those lost in&#xD;
      high-income countries (HIC). Beyond the personal toll, costs related to stroke are&#xD;
      prohibitive and threaten to erode the recent economic gains in Africa where the stroke is a&#xD;
      major threat to brain health, brain capital and human capital. The surge in stroke burden in&#xD;
      Africa is driven by an unprecedented rise in precursory modifiable cardiometabolic risk&#xD;
      factors.&#xD;
&#xD;
      There is an urgent need to deploy evidence-based approaches using the best available&#xD;
      context-specific data to surmount the stroke epidemic on the continent by developing&#xD;
      population-wide preventive interventions. Achieving this goal requires tackling key barriers&#xD;
      to stroke prevention such as lack of awareness and self-directed action to control its risk&#xD;
      factors.&#xD;
&#xD;
      Systematic Investigation of Blacks With Stroke (SIBS-GENOMICS) is poised to utilize the best&#xD;
      available context-specific data on stroke in Africa to improve, validate, and co-create the&#xD;
      first ever Afrocentric stroke riskometer mobile phone application, a self-management tool for&#xD;
      stroke prevention. The app, along with a tailored co-created stroke prevention motivational&#xD;
      video and educational modules with customized behavioral change activities, will be evaluated&#xD;
      for effectiveness to improve individual stroke risk factor awareness and control in the&#xD;
      first-of-its-kind randomized control trial (RCT) for a digital tool for primary stroke&#xD;
      prevention in Africa.&#xD;
&#xD;
      With the scarcity of acute care and rehabilitation services, coupled with the chronic&#xD;
      economic burden imposed by stroke, prevention is evidently the best option towards reducing&#xD;
      its burden in Africa. This is concordant with the core mission of the NINDS to reduce the&#xD;
      burden of stroke in the USA and globally through translational research and innovation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2022</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Actual">November 6, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The relational data model is adopted in the Model component of the system</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigator and outcome assessor will be blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome</measure>
    <time_frame>2 months</time_frame>
    <description>Total stroke risk probability (0 to 100%) calculated by the software. Reduction in total score of at least 10% over 2 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>2 months</time_frame>
    <description>Stroke risk factors awareness score. List of risk factors will be based on SIREN findings and developed into a questionnaire which will be pretested and validated; and translated/back-translated. Change in individual risk factors will also be assessed and compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertension</condition>
  <condition>Adult</condition>
  <condition>Dyslipidemias</condition>
  <condition>Physical Inactivity</condition>
  <condition>Diabetes</condition>
  <condition>Alcohol Consumption</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Control Group will be screened at baseline and be informed of their risk factors. They will be counselled to consult their provider following baseline risk factor assessment but this advice will not be reinforced by exposure to the app, stroke video, or module content. At the end of the study (EOS), they will complete a questionnaire to assess possible contamination with the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The riskometer app will be administered one-on-one to the participants using a smartphone and eventually score and assess them using the global risk score</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Riskometer Application</intervention_name>
    <description>The intervention group participants at baseline will be assessed by installing a riskometer app on their mobile phones to calculate their global stroke risk score. They will be shown their risk scores and the specific risk factors identified through the screening. They will be counselled and supported to manage their risk factors through lifestyle changes and visit their healthcare provider for appropriate care.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Routine Clinic Therapy</intervention_name>
    <description>After their assessment by the blinded adjudicator, the controls will visit the study doctor to obtain the routine clinic therapy and then will be allowed to go home.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female (sex is a biologic variable of interest).&#xD;
&#xD;
          -  age greater than or equal to 18 years.&#xD;
&#xD;
          -  with at least 2 stroke risk factors based on the list of 11 top most modifiable risk&#xD;
             factors identified in the SIREN study (including hypertension, diabetes mellitus,&#xD;
             dyslipidemia, smoking, overweight, physical inactivity, or unbalanced/poor diet).&#xD;
&#xD;
          -  ownership or access to smartphones in consenting stroke-free adults.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior history of vascular disease (e.g., stroke, transient ischemic attack, angina,&#xD;
             myocardial infarction, peripheral vascular disease, and atrial fibrillation), or&#xD;
             cognitive impairment; not comfortable reading and writing, depression or other&#xD;
             psychiatric disorders (through personal declaration) likely to affect the&#xD;
             interventions; participation in another RCT; other conditions rendering the individual&#xD;
             unsuitable to participate in this research as judged by treating physicians.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayowa O. Owolabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>College of Medicine, University of Ibadan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Ovbiagele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred S. Sarfo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kwame Nkrumah University of Science &amp; Technology (KNUST)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin S. Aribisala, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lagos State University, (LASU)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle Nichols, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oyedunni S. Arulogun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ibadan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolyn Jenkins, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bukola Ajala, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ibadan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Onoja M. Akpa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ibadan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Odun J. Akinyemi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ibadan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rufus A. Akinyemi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ibadan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reginald O. Obiako, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ahmadu Bello University Teaching Hospital, (ABUTH) Zaria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mayowa O. Owolabi, MD</last_name>
    <phone>+2348020775595</phone>
    <email>mayowaowolabi@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adekunle G. Fakunle, PhD</last_name>
    <phone>+2348166397832</phone>
    <email>fakunz@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kwame Nkrumah University of Science and Technology (KNUST)</name>
      <address>
        <city>Kumasi</city>
        <zip>00000</zip>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fred S Sarfo, PhD</last_name>
      <email>stephensarfo78@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ahmadu Bello University Teaching Hospital, (ABUTH) Zaria</name>
      <address>
        <city>Zaria</city>
        <state>Kaduna</state>
        <zip>810107</zip>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reginald O Obiako, PhD</last_name>
      <email>orobiako87@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>Ibadan</city>
        <state>Oyo</state>
        <zip>20021</zip>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayowa O Owolabi, MD</last_name>
      <phone>+2348020775595</phone>
      <email>mayowaowolabi@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Adekunle G Fakunle, PhD</last_name>
      <phone>+2348166397832</phone>
      <email>fakunz@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Ghana</country>
    <country>Nigeria</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 24, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Hospital, Ibadan</investigator_affiliation>
    <investigator_full_name>Mayowa Owolabi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stroke-free adults</keyword>
  <keyword>Riskometer App</keyword>
  <keyword>Africans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 5, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT05619406/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

